Given that use of GLP-1 RAs have been associated with muscle loss, an important question that remains is whether repeated GLP-1 RA use and cessation alter body composition in favour of fat mass relative to lean mass, pushing individuals with obesity closer to sarcopenic obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.